As we begin 2026, SGD Pharma CEO Olivier Rousseau reflects on a year of challenges, progress and collective achievements.
Throughout 2025, our teams worked together to strengthen our industrial performance, advance sustainability and support innovation.
Now, we look ahead with a clear strategy. Our priorities for 2026 focus on three key areas: sustainability, operational excellence, and growth and innovation.
Sustainability: Advancing Our Climate Commitments
Sustainability remains a central part of SGD Pharma's strategy for 2026.
We have set a clear target to reduce CO₂ emissions by 42% between 2022 and 2030. The Science Based Targets initiative (SBTi) has validated this commitment.
In 2025, SGD Pharma also earned EcoVadis Platinum status. This recognition places us among the top 1% of glass manufacturers worldwide for ESG performance, according to the assessment highlighted in our year-end message.
Moreover, we plan to build our first hybrid furnace in 2026. This investment will support our efforts to modernize glass manufacturing and reduce its environmental impact.
Together, these initiatives reflect our long-term commitment to more responsible industrial operations.
Operational Excellence: Investing in Our Manufacturing Network
Industrial performance is another major priority.
In 2025, several SGD Pharma business units and manufacturing sites delivered strong results.
At the same time, we committed a record level of capital expenditure (CAPEX) to modernize our furnaces and production lines.
These investments aim to strengthen our manufacturing capabilities and support long-term operational performance.
As a result, we continue to prepare our industrial network for the evolving needs of the pharmaceutical packaging market.
Growth and Innovation: Expanding Our Capabilities
Growth and innovation will also shape SGD Pharma's priorities in 2026.
During 2025, we launched new solutions and accelerated the development of our global tubular glass business.
A major milestone was the acquisition of Alphial. This strategic move strengthens our position in pharmaceutical ampoules and ready-to-use (RTU) vials.
In addition, it expands our capabilities and supports our ambition to serve pharmaceutical customers worldwide.
These developments provide a strong foundation for future growth.
Moving Forward Together in 2026
Our progress would not be possible without the dedication of our employees.
Across SGD Pharma's international teams, colleagues continue to contribute their expertise, commitment and energy every day.
We sincerely thank everyone for their hard work throughout 2025.